US Bitcoin ETFs break outflow streak with $13.3M inflow
Over $1.67 billion exited US spot Bitcoin and Ether exchange-traded funds (ETFs) in March, but investors stopped the bleeding by bringing in $13.3 million on March 12 as the BTC market price inched closer to $85,000.
As of March 12, spot Bitcoin ETFs had attracted $35.4 million worth of inflows spread across two days,
» Read more about: US Bitcoin ETFs break outflow streak with $13.3M inflow »
Read More3 ETFs That Investors Are Plowing Money Into This Year
Personal Finance
The S&P 500 and Nasdaq 100 haven’t been hit this hard in quite a while. With the S&P 500 and Nasdaq 100 correcting, self-guided investors with too much cash may wish to start doing some buying.
» Read more about: 3 ETFs That Investors Are Plowing Money Into This Year »
Read MoreA trade sale for Mainland? Why is Warren Buffett selling ETFs? – Stock Takes
Warren Buffett has been selling ETFs. Photo / File
Materials issued by Fonterra this week suggest the co-op is keeping an open mind to an initial public offer (IPO) for its consumer businesses, but analysts say a trade sale looks to be the most likely option.
Meanwhile,
» Read more about: A trade sale for Mainland? Why is Warren Buffett selling ETFs? – Stock Takes »
Read MoreS&P 500 Dips Closer to Correction Territory
The White House’s tariff threats have sent the S&P 500 spiraling near correction territory, but Treasury Secretary Scott Bessent suggested the Trump administration isn’t worried, for now.
The Dow was down 222 points, or 0.5%, while the S&P 500 was down 0.6%. The Nasdaq Composite was down 1.1%.
» Read more about: S&P 500 Dips Closer to Correction Territory »
Read MoreTrading Plan: Will Nifty, Bank Nifty manage to surpass 20-day EMA?
The Nifty 50 closed with a third-of-a-percent loss amid rangebound trading on March 13, failing to defend the 5-day and 10-day EMAs on a closing basis. The index remained stuck within a range of …
» Read more about: Trading Plan: Will Nifty, Bank Nifty manage to surpass 20-day EMA? »
Read MoreThe Burst
Market Commentary: 1 Stunning Growth Stock Screaming SELL?
1 Stunning Growth Stock Screaming SELL
Read MoreThe Ivy
Down 30%, Is It Time To Buy This Pharma Giant?
Bristol Myers Squibb (BMY) poses something of a conundrum to investors at the moment. On the one hand, the share price has dramatically underperformed the market, leading to concerns that further declines are on the horizon. And on the other hand, the valuation is starting to look really attractive to bargain hunters.
So,
» Read more about: Down 30%, Is It Time To Buy This Pharma Giant? »
Read More